Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy

• Published in: Vaccines (Basel) 2021-12, Vol.9 (12), p.1440
• Main Authors: Cao, Han, Wang, Yunfei, Luan, Ning, Lin, Kangyang, Liu, Cunbao
• Format: Article
• Language: English
• Subjects: Antibodies; Antigens; carboxyl-terminal mutation; Cell-mediated immunity; Chicken pox; Coronaviruses; COVID-19; Disease prevention; Disease transmission; Domains; Endoplasmic reticulum; Endosomes; Enzymes; Fisher, Eugene; Flow cytometry; Ganglia; Gene sequencing; Genomes; Glycoprotein E; Glycoproteins; Golgi apparatus; Humoral immunity; Immunity; Immunogenicity; Immunoglobulin G; Infections; Laboratory animals; Lymphocytes; Lymphocytes T; mRNA; mRNA vaccine; mRNA vaccines; Mutants; Mutation; Proteins; Severe acute respiratory syndrome coronavirus 2; Vaccine efficacy; Vaccines; Variance analysis; Varicella; varicella zoster virus; Viral infections; Viruses
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines9121440

Glycoprotein E (gE) is one of the most abundant glycoproteins in varicella-zoster virus and plays pivotal roles in virus replication and transmission between ganglia cells. Its extracellular domain has been successfully used as an antigen in subunit zoster vaccines. The intracellular C-terminal domain was reported to be decisive for gE trafficking between the endoplasmic reticulum, trans-Golgi network and endosomes and could influence virus spread and virus titers. Considering that the trafficking and distribution of mRNA vaccine-translated gE may be different from those of gE translated against the background of the viral genome (e.g., most gE in virus-infected cells exists as heterodimers with another glycoprotein, gI,), which may influence the immunogenicity of gE-based mRNA vaccines, we compared the humoral and cellular immunity induced by LNP-encapsulated mRNA sequences encoding the whole length of gE, the extracellular domain of gE and a C-terminal double mutant of gE (mutant Y569A with original motif AYRV, which targets gE to TGN, and mutants S593A, S595A, T596A and T598A with the original motif SSTT) that were reported to enhance virus spread and elevate virus titers. The results showed that while the humoral and cellular immunity induced by all of the mRNA vaccines was comparable to or better than that induced by the AS01B-adjuvanted subunit vaccines, the C-terminal double mutant of gE showed stable advantages in all of the indicators tested, including gE-specific IgG titers and T cell responses, and could be adopted as a candidate for both safer varicella vaccines and effective zoster vaccines.